Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.50% | 43.97 | 0.9% | $1186.44m | |
| ABBV | AbbVie, Inc. | -0.22% | 107.12 | 1.9% | $1023.77m | |
| JNJ | Johnson & Johnson | -0.23% | 164.48 | 0.7% | $988.09m | |
| MRK | Merck & Co., Inc. | 0.81% | 73.64 | 0.7% | $914.30m | |
| LLY | Eli Lilly & Co. | -0.26% | 231.58 | 1.1% | $588.95m | |
| BMY | Bristol-Myers Squibb Co. | -0.61% | 60.26 | 1.0% | $575.61m | |
| AZN | AstraZeneca Plc | 1.46% | 60.35 | 1.0% | $353.10m | |
| NVS | Novartis AG | -0.75% | 82.95 | 0.2% | $156.40m | |
| CRVS | Corvus Pharmaceuticals, Inc. | -3.27% | 6.80 | 0.7% | $140.27m | |
| GSK | GlaxoSmithKline Plc | -2.44% | 38.38 | 0.2% | $135.32m | |
| RGEN | Repligen Corp. | -0.29% | 323.26 | 6.8% | $123.14m | |
| SNY | Sanofi | -1.60% | 47.94 | 0.2% | $122.20m | |
| RPRX | Royalty Pharma Plc | -0.08% | 37.10 | 0.1% | $121.13m | |
| VTRS | Viatris, Inc. | 0.30% | 13.38 | 0.0% | $107.54m | |
| NVO | Novo Nordisk A/S | -1.36% | 100.71 | 0.1% | $101.76m |
Company Profile
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.